Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339069 | 0.81 | RECQL (0.36) | SLC6A2SLC6A4 | |
| SCHEMBL8180505 | 0.79 | CYP19A1 (0.42) | CYP19A1ACHEMAPTTBXA2RSLC6A2 | |
| SCHEMBL6936648 | 0.75 | CYP19A1 (0.40) | CYP19A1MAPTTBXA2RSLC6A2SLC6A4 | |
| SCHEMBL6338888 | 0.73 | SLC6A2 (0.35) | SLC6A2SLC6A4 | |
| SCHEMBL6935322 | 0.72 | CYP19A1 (0.39) | CYP19A1MAPT | |
| SCHEMBL6347611 | 0.72 | CYP19A1 (0.41) | CYP19A1ACHEMAPTHSP90AA1 | |
| SCHEMBL6339196 | 0.70 | PSEN1 (0.34) | MAPT | |
| SCHEMBL6347584 | 0.69 | HSP90AA1 (0.43) | MAPTHSP90AA1 | |
| SCHEMBL6350114 | 0.69 | HSP90AA1 (0.47) | MAPTHSP90AA1 | |
| SCHEMBL6558637 | 0.69 | KCNE1 (0.40) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908947-B2 | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-0861836-B1 | Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity | AVENTIS PHARMA GMBH (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20020072514-A1 | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them | HOECHST AKTIENGESELLSCHAFT | 2002-06-13 | — | — | US | disclosed |
| US-6333349-B1 | POTASSIUM CHANNEL OR THE I.SUB.KS CHANNEL OPENED BY CYCLIC ADENOSINE MONOPHOSPHATE AS POTASSIUM CHANNEL ACTIVATORS AND CARDIOVASCULAR DISORDERS, ANTIARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL REGION OR FOR THE TREATMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
| EP-0861836-A1 | Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072514-A1 | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them | KCNN3, KCNJ1, KCNJ11 | CYP19A1 3172/4885ACHE 2594/4885MAPT 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.